Patients undergoing cardiac catheterization who are given oral Nicorandil experience less contrast-induced nephropathy.

Published Date: 08 Sep 2023

Iran: Oral nicorandil may help reduce the occurrence of contrast-induced nephropathy in patients undergoing cardiac catheterization.

Read Full News

Latest News

Professional Corner: What’s New in Primary Care?

A new survey examines young adults’ use of primary care, Nebraska receives funding for rural training, and Trinity Health expands services in West Michigan.

Maternal BMI and Birth Length Tied to Dermatitis Risk

A higher maternal prepregnancy BMI and greater birth length are associated with an elevated risk for atopic dermatitis in offspring by 3 years of age, new research shows.

Diabetologists On the Rise as Disease Overwhelms Practices

The launch of the American College of Diabetology has helped dozens of physicians become board-certified, with more on the way.

CMA Funds Program to HELP International Physicians Practice

A new commitment will support a program that familiarizes internationally trained physicians with medical English and the Canadian healthcare system.

Doctors Fired After Unionizing Win Settlement From Employer

Peak Vista Community Health Centers will pay $1.2 million to four physicians and a nurse practitioner after a decision by the National Labor Relations Board.

Todays Updates

8 Pulmonology Headlines You Missed in Q3 2026

8 Pulmonology Headlines You Missed in Q3 2026

Phase 3 PROPEL Trial to Test Imeroprubart in Generalized Myasthenia Gravis Marco Meglio

PROPEL will test imeroprubart, an investigational FcRn blocker, against placebo in adults with mild to severe generalized myasthenia gravis.

This Week on NeurologyLive® — October 5, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Ecopipam Shows Early and Sustained Tic Reduction in New Pediatric Tourette Syndrome Analyses Louie Pasculli

New analyses from the D1AMOND clinical program found that 69.8% of participants achieved a clinically meaningful reduction in tic severity within 8 weeks of ecopipam treatment, while an interim 18-month analysis showed sustained improvement without new safety signals.

LRRK2 Inhibitor BIIB122 Fails to Slow Early-Stage Parkinson Disease Marco Meglio

Full results from the phase 2b LUMA showed that investigational BIIB122/DNL151 did not slow confirmed clinical worsening in early-stage Parkinson's disease compared with placebo.

Phase 1 Data Link ARV-102 LRRK2 Degradation to Oculomotor and CSF Biomarker Changes in Parkinson Disease Louie Pasculli

Early phase 1 findings showed that the PROTAC LRRK2 degrader ARV-102 was associated with improvements in saccadic hypometria and changes in CSF markers of endolysosomal function, neuroinflammation, synaptic integrity, and axonal guidance in participants with Parkinson disease.

6 Nephrology Headlines You Missed in September 2026

6 Nephrology Headlines You Missed in September 2026

Todays Updates

8 Pulmonology Headlines You Missed in Q3 2026

8 Pulmonology Headlines You Missed in Q3 2026

Phase 3 PROPEL Trial to Test Imeroprubart in Generalized Myasthenia Gravis Marco Meglio

PROPEL will test imeroprubart, an investigational FcRn blocker, against placebo in adults with mild to severe generalized myasthenia gravis.

This Week on NeurologyLive® — October 5, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Ecopipam Shows Early and Sustained Tic Reduction in New Pediatric Tourette Syndrome Analyses Louie Pasculli

New analyses from the D1AMOND clinical program found that 69.8% of participants achieved a clinically meaningful reduction in tic severity within 8 weeks of ecopipam treatment, while an interim 18-month analysis showed sustained improvement without new safety signals.

LRRK2 Inhibitor BIIB122 Fails to Slow Early-Stage Parkinson Disease Marco Meglio

Full results from the phase 2b LUMA showed that investigational BIIB122/DNL151 did not slow confirmed clinical worsening in early-stage Parkinson's disease compared with placebo.

Phase 1 Data Link ARV-102 LRRK2 Degradation to Oculomotor and CSF Biomarker Changes in Parkinson Disease Louie Pasculli

Early phase 1 findings showed that the PROTAC LRRK2 degrader ARV-102 was associated with improvements in saccadic hypometria and changes in CSF markers of endolysosomal function, neuroinflammation, synaptic integrity, and axonal guidance in participants with Parkinson disease.

6 Nephrology Headlines You Missed in September 2026

6 Nephrology Headlines You Missed in September 2026

Latest News

A new survey examines young adults’ use of primary care, Nebraska receives funding for rural training, and Trinity Health expands services in West Michigan.

A higher maternal prepregnancy BMI and greater birth length are associated with an elevated risk for atopic dermatitis in offspring by 3 years of age, new research shows.

The launch of the American College of Diabetology has helped dozens of physicians become board-certified, with more on the way.

A new commitment will support a program that familiarizes internationally trained physicians with medical English and the Canadian healthcare system.

Peak Vista Community Health Centers will pay $1.2 million to four physicians and a nurse practitioner after a decision by the National Labor Relations Board.

News All Time

The CDSCO panel approves AstraZeneca's study of the antihypertensive medication baxdrostat.

New Delhi: Under the Central Drug Standard Control, the Subject Expert Committee (SEC) has granted approval to AstraZeneca, a major pharmaceutical company.

Check the facts: Posts on social media asserting that biology is not necessary for NEET UG are false.

posts on social media asserting that biology coursework is no longer necessary for those aspiring to become doctors in order to take the National Eligibility-cum-Entrance Test.

Kerala High Court orders Time-Bound Immediate Investigation into Unnecessary Embarrassment of Doctors from Delayed Medical Negligence Probe.

New Delhi: The Kerala High Court on Monday highlighted the possibility that physicians who are innocent could be subjected to needless humiliation should the investigation delay.

Eugene A. Woods joins the board of directors at JnJ.

Johnson and Johnson has announced in New Brunswick that Eugene A. The new CEO of Advocate Health is Woods, MBA, MHA.

Only 30% of doctors' families who passed away from COVID-19 received compensation up until 2023:RTI.

In response to a Right to Information query asking about the total Covid martyrs compensated under the Pradhan Mantri Garib Kalyan Package (PMGKP),.

Medical students from Manipur who have been displaced are able to pursue their education via online or hybrid modes thanks to NMC.

The Undergraduate Medical Education Board (UGMEB) of the National Medical Commission (NMC) has permitted displaced parties, providing a remarkable reprieve.

Incorporate the Ankle Brachial Index examination to rule out peripheral artery disease: A CDSCO Panel Notifies Lupin Regarding Denosumab PK/PD Research.

New Delhi: Under the Central Drug Standard Control, the Subject Expert Committee (SEC) has approved the drug major Lupin.

Delhi High Court: MCI sanctions cannot be used as a yardstick for determining a doctor's shortcomings, flaws, or insufficiency.

New Delhi: The Delhi High Court recently declared that the punishment awarded by the MCI, which is now the National Medical Commission (NMC), could not be an.

As per JAMA, Prone Positioning Has No Effect on the Length of ECMO Weaning in Covid Patients with Severe ARDS.

According to Matthieu Schmidt and colleagues, a randomized clinical trial examined the effects of prone positioning on patients suffering from severe acute respiratory distress.

Rituximab and glucocorticoids in Wegener's Granulomatosis: A PMS Study Report approved by the CDSCO Panel.

New Delhi: The Central Drug Standard Control Organization (CDSCO)'s Subject Expert Committee (SEC) has authorized a post-marketing.

The manufacture and marketing of Azelnidipine and Metoprolol FDC tablets has been approved by the CDSCO Panel for Akum Pharmaceutical.

New Delhi: The Subject Expert Committee (SEC) operating under the Central Drug Standard has given the go-ahead to the pharmaceutical giant Akum Pharmaceuticals.

Health Bulletin / November 30, 2023.

Following a spike in respiratory cases, Uttarakhand and Karnataka are on alert due to a pneumonia outbreak in China. These are the top health stories of the day.

The MP government issues a directive to Yatharth Hospital to assume control of the Ramraja Hospital grounds.

MP: As a result of an order from the Commissionerate of Sagar Sambhag, Madhya, Yatharth Hospital experienced significant trouble yesterday.

Check Your Information: Media reports asserting that biology is not necessary for NEET UG are false.

New Delhi: Posts on social media assert that biology coursework is no longer necessary for applicants to the National Exam to pursue careers in medicine.

The deadline to submit course preferences, willingness to work, and fee for the special straw vacancy round for PG medical seats in Puducherry is today.

The Centralized Admission Committee (CENTAC) in Puducherry has released a notification concerning the special stray vacancy round for three open NEET PG seats.

A radiologist found guilty of violating the PC PNDT Act received a two-year rigorous prison sentence.

A session court in Jabalpur has found a DMRD doctor guilty of a heinous violation of the Pre-Conception and Pre-Natal Diagnostic Techniques (PCPNDT) Act.

Recommended News For You

Muscle Strength, Fitness Linked to Lower Mortality Risk in Patients With Cancer

Germline Variants Predict Lobular Breast Cancer Recurrence

What Role Should Genomic Classifier Testing Play in Prostate Cancer?

FDA Approves ctDNA-Guided Atezolizumab for Bladder Cancer

Genetics and therapy type determine second cancer risk after childhood treatment, study finds

Early breast cancer detection may be possible with a wearable ultrasound scanner.

PET-CT is better than contrast-enhanced CT as a predictor of survival in patients with metastatic breast cancer

Recommended Articles For You

Breaking Barriers: Innovative Approaches in Brain Tumor Treatment 

Tumor Microenvironment Reprogramming Through Stromal Modulation 

The Precision Revolution: Bispecific Antibodies and Antibody-Drug Conjugates Reshaping the Oncology Landscape 

Understanding Epidural Hematoma: Symptoms, Causes and Treatment  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The New Perfectionism Problem in Medical Training

2.

How Low Does PSA Need to Go in Metastatic Prostate Cancer?

3.

Detecting invasive nodules could be key to preventing unnecessary pancreatic cancer surgery

4.

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

5.

Retifanlimab-Chemo Combo Boosts PFS in Advanced Squamous Cell Anal Cancer

1.

Progressive Updates in Oncology for Healthcare Excellence

2.

Precision Erythropoietic Modeling for Hematologic Disorders

3.

Unlocking the Potential of Reticulocytes: The Key to Enhanced Blood Production

4.

Molecular Matching for Precision Cancer Therapy

5.

Oncology Trials Roadmap: From Drug Discovery to Delivery and Patient Access

1.

International Conference on Cancer Nursing and Rehabilitation Strategies

2.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

3.

International Conference on Innovations in Critical Care for Oncology and Cardiology

4.

International Symposium on Oncology, Cardiology and Critical Care Innovations

5.

International Conference on Cancer Nursing and Hematology Support

1.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII

2.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

3.

Case-Based Learning: Oncology

4.

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

5.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot